medigraphic.com
ISSN 1527-3172 (Electronic)

2011, Number 3

<< Back Next >>

MEDICC Review 2011; 13 (3)

Global pharmaceutical development and access: Critical issues of Ethics and Equity

Lage A

Language: Spanish
References: 27
Page: 1-8
PDF size: 226.95 Kb.


ABSTRACT

The article presents global data on access to pharmaceuticals and discusses underlying barriers. Two are highly visible: pricing policies and intellectual property rights; two are less recognized: the regulatory environment and scientific and technological capacities. Two ongoing transitions influence and even distort the problem of universal access to medications: the epidemiologic transition to an increasing burden of chronic non-communicable diseases; and the growing role of biotechnology products (especially immunobiologicals) in the pharmacopeia. Examples from Cuba and Brazil are used to explore what can and should be done to address commercial, regulatory, and technological aspects of assuring universal access to medications.


REFERENCES

  1. Perehudoff SK. Health, Essential Medications. Human Rights & National Constitutions. Bull World Health Organ [Internet]. 2008 Jul [cited 2011 Mar 18]. Available from: http://www.who.int/ medicines/areas/human_rights/Perehudoff_report_ constitutions_2008.pdf

  2. Perehudoff SK, Laing RO, Hogerzeil HV. Access to essential medications in national constitutions. Bull World Health Organ. 2010 Nov 1;88(11):800.

  3. WHO Medications Strategy. Countries at the core 2004–2007. Geneva: World Health Organization; 2004. 12 p.

  4. Gelders S, Ewen M, Noguchi N, Laing R. Price, availability and affordability. An international comparison of chronic disease medications [Internet]. Cairo: World Health Organization; 2005 Dec [cited 2011 Mar 18]. 69 p. Available from:

  5. http://www.haiweb.org/medicinepric- es/08092008/EDB068fi nal.pdf

  6. WHO. Measuring medicine prices, availability, affordability and price components. 2nd ed. Geneva: World Health Organization; 2008. [disponible en español en: apps.who.int/medicinedocs/documents/ s16876s/s16876s.pdf—Ed.]6. Jacobzone S. IDEAS [Internet]. Connecticut: University of Connecticut. 2000 Apr. Record No. 40, Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals; [cited 2011 Mar 18]; [about 2 screens]. Available from: http://ideas. repec.org/p/oec/elsaaa/40-en.html

  7. The European Parliament. Strategies for the Improvement of Global Human Health [Internet]. Strasbourg: The European Parliament; 2006 Jun 29 [cited 2011 Mar 18]. 55 p. Available from: http://www.itas.fzk.de/eng/etag/document/2006/ elde06a.pdf

  8. Newcomer LN. The Responsibility to Pay for Cancer Treatments: A Health Insurer’s View of Value. Oncologist. 2010;15 Suppl 1:32–5.

  9. Resnik DB. The Distribution of Biomedical Research Resources and International Justice. Dev World Bioeth. 2004 May;4(1):42–57.

  10. WHO. The World Health Report–Health Systems Financing: the Path to Universal Coverage [Internet]. Geneva: World Health Organization; 2010 Nov 22 [cited 2011Mar 18]. Available from: http:// www.who.int/whr/2010/whr10_en.pdf

  11. Kerry VB, Lee K. TRIPS, the Doha declaration and paragraph 6 decisions: what are the remaining steps for protecting access to medications? Global Health. 2007 May 24;3:3.

  12. WHO. Public health. Innovation and Intellectual. Property Rights. Report of the Commission on Intellectual Property Rights. Geneva: World Health Organization; 2006.

  13. Hoen E. Report of the Commission on Intellectual Property Rights, Innovation and Public Health: a call to governments. Bull World Health Organ. 2006 May;84(5):421–3.

  14. Noehrenberg E. Report of the Commission on Intellectual Property Rights, Innovation and Public Health: an industry perspective. Bull World Health Organ. 2006 May;84(5):419– 20.

  15. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability,

  16. and affordability in 36 developing and middleincome countries: a secondary analysis. Lancet. 2009 Jan 17;373(9659):240–9.

  17. Creese A, Gasman N, Mariko M. The world medications situation. Geneva: World Health Organization; 2004.

  18. Fojo T, Grady C. How Much Is Life Worth: Cetuximab, Non–Small Cell Lung Cancer, and the $440 Billion Question. J Natl Cancer Inst. 2009 Aug 5;101(15):1044–8.

  19. UNESCO. Science Report 2010 [Internet]. Paris: UNESCO Publishing; 2010 Nov 10 [cited 2011 Mar 18]. 541 p. Available from: http://unesdoc. unesco.org/images/0018/001899/189958e. pdf

  20. Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, et al. The availability and affordability of selected essential medications for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007 Apr;85(4):279–88.

  21. Chu R, Pugatch M. Biogenerics or Biosimilars? Discussing the Present, Considering the Future. London: Stockholm Network; 2009 Oct. 31 p.

  22. EvaluatePharma® World Preview 2016 – Analysis Highlights. London: Evaluate Pharma; 2010 May. 31 p.

  23. Lage A. Connecting immunology research to public health: Cuban biotechnology. Nat Immunol. 2008 Feb;9(2):109–12.

  24. Van Puymbroeck RV. Basic Survival Needs and Access to medications–Coming to Grips with TRIPS: Conversion + Calculation. J Law Med Ethics. 2010 Fall;38(3):520–49.

  25. Lage A. Transforming Cancer Indicators Begs Bold New Strategies from Biotechnology.

  26. MEDICC Rev. 2009 Jul;11(3):8–12.

  27. Lage A, Crombet T. Control of Advanced Cancer: The Road to Chronicity. Int J Environ Res Public Health. 2011 Mar;8(3):683–97.




2020     |     www.medigraphic.com